These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864 [TBL] [Abstract][Full Text] [Related]
9. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor. Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773 [TBL] [Abstract][Full Text] [Related]
11. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Do R; Kiss RS; Gaudet D; Engert JC Clin Genet; 2009 Jan; 75(1):19-29. PubMed ID: 19054015 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Ishihara T; Kakuta H; Moritani H; Ugawa T; Yanagisawa I Bioorg Med Chem; 2004 Nov; 12(22):5899-908. PubMed ID: 15498666 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. Brown GR; Clarke DS; Foubister AJ; Freeman S; Harrison PJ; Johnson MC; Mallion KB; McCormick J; McTaggart F; Reid AC; Smith GJ; Taylor MJ J Med Chem; 1996 Jul; 39(15):2971-9. PubMed ID: 8709131 [TBL] [Abstract][Full Text] [Related]
14. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728 [TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152 [TBL] [Abstract][Full Text] [Related]
16. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Ugawa T; Kakuta H; Moritani H; Inagaki O; Shikama H Br J Pharmacol; 2003 May; 139(1):140-6. PubMed ID: 12746232 [TBL] [Abstract][Full Text] [Related]
17. Thiomorpholine Derivatives with Hypolipidemic and Antioxidant Activity. Tooulia KK; Theodosis-Nobelos P; Rekka EA Arch Pharm (Weinheim); 2015 Sep; 348(9):629-34. PubMed ID: 26191791 [TBL] [Abstract][Full Text] [Related]
18. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Ugawa T; Kakuta H; Moritani H; Matsuda K; Ishihara T; Yamaguchi M; Naganuma S; Iizumi Y; Shikama H Br J Pharmacol; 2000 Sep; 131(1):63-70. PubMed ID: 10960070 [TBL] [Abstract][Full Text] [Related]
19. Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors. Griebenow N; Flessner T; Buchmueller A; Raabe M; Bischoff H; Kolkhof P Bioorg Med Chem Lett; 2011 Apr; 21(8):2554-8. PubMed ID: 21396815 [TBL] [Abstract][Full Text] [Related]
20. Design of more potent squalene synthase inhibitors with multiple activities. Kourounakis AP; Matralis AN; Nikitakis A Bioorg Med Chem; 2010 Nov; 18(21):7402-12. PubMed ID: 20888243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]